Analyst Price Targets — DNLI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 26, 2026 12:36 pm | — | Deutsche Bank | $35.00 | $19.74 | TheFly | Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank |
| March 2, 2026 10:08 pm | Andrew Tsai | Jefferies | $40.00 | $21.00 | StreetInsider | Jefferies Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) |
| January 8, 2026 12:43 pm | Sean Laaman | Morgan Stanley | $40.00 | $16.95 | TheFly | Denali Therapeutics price target raised to $40 from $32 at Morgan Stanley |
| January 7, 2026 5:41 am | Michael Yee | UBS | $25.00 | $17.21 | StreetInsider | UBS Assumes Denali Therapeutics Inc. (DNLI) at Buy |
| December 11, 2025 1:30 pm | Laura Chico | Wedbush | $30.00 | $17.61 | TheFly | Denali Therapeutics price target lowered to $30 from $31 at Wedbush |
| December 5, 2025 12:44 pm | Laura Chico | Wedbush | $31.00 | $20.11 | TheFly | Denali Therapeutics price target raised to $31 from $30 at Wedbush |
| November 17, 2025 2:28 pm | Paul Mattels | Stifel Nicolaus | $37.00 | $17.67 | StreetInsider | Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) |
| January 7, 2025 12:22 pm | Thomas Shrader | BTIG | $32.00 | $21.18 | TheFly | Denali Therapeutics price target lowered to $32 from $35 at BTIG |
| November 1, 2024 9:46 am | Michael Yee | Jefferies | $45.00 | $27.05 | StreetInsider | Denali Therapeutics Inc. (DNLI) PT Raised to $45 at Jefferies |
| October 14, 2024 6:04 am | Thomas Shrader | BTIG | $35.00 | $28.00 | StreetInsider | BTIG Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) |
Latest News for DNLI
DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and Takedas exit complicate the outlook.
DNLI's shares decline after Takeda exits DNL593 partnership, leaving Denali to fully control and fund the therapy as it advances studies and plans 2026 data release.
Takeda on Friday notified Denali Therapeutics regarding the termination of their collaboration agreement to co-develop DNL593, a progranulin replacement therapy for frontotemporal dementia.
Capricorn Fund Managers Ltd acquired a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 62,197 shares of the company's stock, valued at approximately $1,027,000. Other institutional investors and hedge funds
SG Americas Securities LLC boosted its holdings in Denali Therapeutics Inc. (NASDAQ: DNLI) by 291.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 149,592 shares of the company's stock after buying an additional 111,391 shares during the period. SG Americas
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DNLI.
U.S. House Trading
No House trades found for DNLI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.